{"transactions":[{"id":767488,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-21T20:30:06.000Z","date":"2026-05-19","kind":"gift","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes."}],"balance_after":160000,"source":{"system":"sec-edgar","filing":"0001193125-26-234578","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000119312526234578/ownership.xml","form_type":"4"}},{"id":767487,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-21T20:30:06.000Z","date":"2026-05-19","kind":"gift","planned":false,"acquired":false,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes."}],"balance_after":497503,"source":{"system":"sec-edgar","filing":"0001193125-26-234578","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000119312526234578/ownership.xml","form_type":"4"}},{"id":961829,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-19T21:01:10.000Z","date":"2025-12-17","kind":"grant","planned":false,"acquired":true,"shares":245000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates."}],"balance_after":245000,"derivative":{"exercise_price":39.45,"expiration_date":"2035-12-17","underlying":"Common Stock","underlying_shares":245000},"source":{"system":"sec-edgar","filing":"0001193125-25-326775","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000119312525326775/ownership.xml","form_type":"4"}},{"id":961828,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-19T21:01:10.000Z","date":"2025-12-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":367497,"price":39.45,"value":14497756.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":657503,"source":{"system":"sec-edgar","filing":"0001193125-25-326775","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000119312525326775/ownership.xml","form_type":"4"}},{"id":961827,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-19T21:01:10.000Z","date":"2025-12-17","kind":"grant","planned":false,"acquired":true,"shares":840000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the \"2023 PSUs\")."}],"balance_after":1025000,"source":{"system":"sec-edgar","filing":"0001193125-25-326775","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000119312525326775/ownership.xml","form_type":"4"}},{"id":961826,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-19T21:01:10.000Z","date":"2025-12-17","kind":"grant","planned":false,"acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates."}],"balance_after":185000,"source":{"system":"sec-edgar","filing":"0001193125-25-326775","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000119312525326775/ownership.xml","form_type":"4"}},{"id":1294259,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-27T21:56:09.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":915000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in equal monthly installments over a four year period."}],"balance_after":915000,"derivative":{"exercise_price":8.89,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":915000},"source":{"system":"sec-edgar","filing":"0000950170-25-009257","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000095017025009257/ownership.xml","form_type":"4"}},{"id":1583554,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-03-11T21:18:48.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":6.657,"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0000950170-24-029433","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000095017024029433/ownership.xml","form_type":"4"}},{"id":1583553,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-03-11T21:18:48.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1016,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":20.1,"underlying":"Common Stock","underlying_shares":1016},"source":{"system":"sec-edgar","filing":"0000950170-24-029433","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000095017024029433/ownership.xml","form_type":"4"}},{"id":1583552,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T21:18:48.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 5,000 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the \"Common Stock Merger Consideration\")."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-029433","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000095017024029433/ownership.xml","form_type":"4"}},{"id":1670667,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-25T21:20:02.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":1100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in equal monthly installments over a four year period."}],"balance_after":1100000,"derivative":{"exercise_price":4.63,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":1100000},"source":{"system":"sec-edgar","filing":"0000950170-24-007414","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000095017024007414/ownership.xml","form_type":"4"}},{"id":1728323,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-28T21:28:20.000Z","date":"2023-11-27","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the settlement of restricted stock units (\"RSUs\"). 25% of the RSUs will vest on each May 27th and November 27th of 2024 and 2025, subject to acceleration and vesting in full upon a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan) of the Issuer, and subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-23-056798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000120919123056798/doc4.xml","form_type":"4"}},{"id":1844879,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-23T20:38:28.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on June 21, 2024, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":23000,"derivative":{"exercise_price":0.6657,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-23-039420","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000120919123039420/doc4.xml","form_type":"4"}},{"id":2013188,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-15T20:49:14.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in equal monthly installments over a four year period."}],"balance_after":525000,"derivative":{"exercise_price":13.63,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000899243-23-005135","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000089924323005135/doc4.xml","form_type":"4"}},{"id":2221800,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-06-24T22:49:27.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on June 21, 2023, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":2.01,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-22-039328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000120919122039328/doc4.xml","form_type":"4"}},{"id":2423796,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-27T22:37:42.000Z","date":"2022-01-25","kind":"grant","acquired":true,"shares":690000,"price":4.9432,"value":3410808.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in equal monthly installments over a four year period."}],"balance_after":690000,"derivative":{"exercise_price":7.6,"expiration_date":"2032-01-25","underlying":"Common Stock","underlying_shares":690000},"source":{"system":"sec-edgar","filing":"0000899243-22-003462","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000089924322003462/doc4.xml","form_type":"4"}},{"id":2711893,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-15T00:05:40.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This option was erroneously reported with a price of $22.50 on the original Form 4 filed on May 7, 2021 due to an administrative error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will fully vest and become exercisable on May 3, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date. The original Form 4 filed on May 7, 2021 erroneously reported this vesting date as May 4, 2022."}],"balance_after":10167,"derivative":{"exercise_price":23.2,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-21-032965","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000120919121032965/doc4a.xml","form_type":"4/A","original_submission_date":"2021-05-07"}},{"id":2722423,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-08T01:57:22.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on May 4, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":22.5,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-21-031108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000120919121031108/doc4.xml","form_type":"4"}},{"id":2862391,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-13T01:17:53.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":315200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in equal monthly installments over a four year period."}],"balance_after":315200,"derivative":{"exercise_price":10.17,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":315200},"source":{"system":"sec-edgar","filing":"0000899243-21-006403","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000089924321006403/doc4.xml","form_type":"4"}},{"id":2951175,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-10T02:09:40.000Z","date":"2020-12-07","kind":"grant","acquired":true,"shares":456693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest over a four year period as follows: 1/4th of the option shall vest one year after the vesting start date; then 1/48th of the option shall vest monthly over the remaining three year period."}],"balance_after":456693,"derivative":{"exercise_price":12.76,"expiration_date":"2030-12-07","underlying":"Common Stock","underlying_shares":456693},"source":{"system":"sec-edgar","filing":"0000899243-20-033232","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000089924320033232/doc4.xml","form_type":"4"}},{"id":2999161,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-27T20:05:11.000Z","date":"2020-10-23","kind":"grant","acquired":true,"shares":7442421,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest as follows: 25% on the first anniversary of the date of grant; then in equal monthly installments over 36 months."}],"balance_after":7442421,"derivative":{"exercise_price":2.79,"expiration_date":"2030-10-22","underlying":"Common Stock","underlying_shares":7442421},"source":{"system":"sec-edgar","filing":"0001209191-20-055909","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000120919120055909/doc4.xml","form_type":"4"}},{"id":3188676,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-04-01T21:18:23.000Z","date":"2020-03-30","kind":"grant","acquired":true,"shares":20335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in three equal annual installments measured from the date of grant, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":20335,"derivative":{"exercise_price":11.78,"expiration_date":"2030-03-29","underlying":"Common Stock","underlying_shares":20335},"source":{"system":"sec-edgar","filing":"0001209191-20-022193","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590157/000120919120022193/doc4.xml","form_type":"4"}},{"id":3453473,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:04:27.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":315750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option provided for vesting in four equal annual installments beginning on December 16, 2019."}],"balance_after":0,"derivative":{"exercise_price":15.97,"expiration_date":"2028-12-16","underlying":"Common Stock","underlying_shares":315750},"source":{"system":"sec-edgar","filing":"0001209191-19-043782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043782/doc4.xml","form_type":"4"}},{"id":3453472,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:04:27.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":335250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option provided for vesting in four equal annual installments beginning on December 16, 2018."}],"balance_after":0,"derivative":{"exercise_price":10.92,"expiration_date":"2027-12-16","underlying":"Common Stock","underlying_shares":335250},"source":{"system":"sec-edgar","filing":"0001209191-19-043782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043782/doc4.xml","form_type":"4"}},{"id":3453471,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:04:27.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":313989,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option provided for vesting in four equal annual installments beginning on December 26, 2017."}],"balance_after":0,"derivative":{"exercise_price":8.79,"expiration_date":"2026-12-27","underlying":"Common Stock","underlying_shares":313989},"source":{"system":"sec-edgar","filing":"0001209191-19-043782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043782/doc4.xml","form_type":"4"}},{"id":3453470,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:04:27.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":236250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option provided for vesting in four equal annual installments beginning on April 1, 2017."}],"balance_after":0,"derivative":{"exercise_price":3,"expiration_date":"2026-04-01","underlying":"Common Stock","underlying_shares":236250},"source":{"system":"sec-edgar","filing":"0001209191-19-043782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043782/doc4.xml","form_type":"4"}},{"id":3453469,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:04:27.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":236250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option provided for vesting in four equal annual installments beginning on April 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":7.3,"expiration_date":"2025-04-01","underlying":"Common Stock","underlying_shares":236250},"source":{"system":"sec-edgar","filing":"0001209191-19-043782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043782/doc4.xml","form_type":"4"}},{"id":3453468,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:04:27.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option provided for vesting in four equal annual installments beginning on March 2, 2016."}],"balance_after":0,"derivative":{"exercise_price":8.2,"expiration_date":"2025-03-02","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-043782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043782/doc4.xml","form_type":"4"}},{"id":3453467,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2019-07-30T20:04:27.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":130542,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 14, 2019, Array BioPharma Inc. (the \"Company\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Pfizer Inc. (\"Pfizer\") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer (\"Purchaser\"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares of Company common stock underlying each restricted stock unit (a \"Company RSU\") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-043782","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043782/doc4.xml","form_type":"4"}},{"id":3453466,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2019-07-30T20:04:27.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":71022,"price":48,"value":3409056.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 14, 2019, Array BioPharma Inc. (the \"Company\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Pfizer Inc. (\"Pfizer\") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer (\"Purchaser\"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."}],"balance_after":130542,"source":{"system":"sec-edgar","filing":"0001209191-19-043782","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043782/doc4.xml","form_type":"4"}},{"id":3565849,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2019-04-03T16:31:11.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":9844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest and will be settled in stock in four equal installments beginning April 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest and will be settled in stock in four equal installments beginning April 1, 2016."}],"balance_after":9844,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9844},"source":{"system":"sec-edgar","filing":"0001562180-19-002184","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019002184/primarydocument.xml","form_type":"4"}},{"id":3565848,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2019-04-03T16:31:11.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":9844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested and settled in stock in four equal installments beginning April 1, 2015."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested and settled in stock in four equal installments beginning April 1, 2015."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9844},"source":{"system":"sec-edgar","filing":"0001562180-19-002184","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019002184/primarydocument.xml","form_type":"4"}},{"id":3565847,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2019-04-03T16:31:11.000Z","date":"2019-04-01","kind":"tax_withholding","acquired":false,"shares":8660,"price":24.6,"value":213036.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person."}],"balance_after":71022,"source":{"system":"sec-edgar","filing":"0001562180-19-002184","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019002184/primarydocument.xml","form_type":"4"}},{"id":3565846,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2019-04-03T16:31:11.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":19688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares issued upon settlement of Restricted Stock Units (\"RSUs\") granted on April 1, 2015 and April 1, 2016, as a result of the vesting of one fourth of such RSUs."}],"balance_after":79682,"source":{"system":"sec-edgar","filing":"0001562180-19-002184","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019002184/primarydocument.xml","form_type":"4"}},{"id":3668773,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T18:36:01.000Z","date":"2019-02-06","kind":"exercise","acquired":false,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in four equal annual installments beginning on April 1, 2015."}],"balance_after":0,"derivative":{"exercise_price":4.63,"expiration_date":"2024-04-01","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001562180-19-000862","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000862/primarydocument.xml","form_type":"4"}},{"id":3668772,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T18:36:01.000Z","date":"2019-02-06","kind":"exercise","acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning on March 2, 2016."}],"balance_after":12500,"derivative":{"exercise_price":8.2,"expiration_date":"2025-03-02","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001562180-19-000862","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000862/primarydocument.xml","form_type":"4"}},{"id":3668771,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2019-02-08T18:36:01.000Z","date":"2019-02-06","kind":"sale","acquired":false,"shares":239626,"price":20.025,"value":4798510.65,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported for these shares is the weighted average sale price of transactions made at prices from $20.00 to $20.20. Details of actual prices for shares sold are available from the Issuer upon request."}],"balance_after":59994,"source":{"system":"sec-edgar","filing":"0001562180-19-000862","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000862/primarydocument.xml","form_type":"4"}},{"id":3668770,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2019-02-08T18:36:01.000Z","date":"2019-02-06","kind":"exercise","acquired":true,"shares":87500,"price":4.63,"value":405125.0,"ownership":{"direct":true},"balance_after":299620,"source":{"system":"sec-edgar","filing":"0001562180-19-000862","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000862/primarydocument.xml","form_type":"4"}},{"id":3668769,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2019-02-08T18:36:01.000Z","date":"2019-02-06","kind":"exercise","acquired":true,"shares":37500,"price":8.2,"value":307500.0,"ownership":{"direct":true},"balance_after":212120,"source":{"system":"sec-edgar","filing":"0001562180-19-000862","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000862/primarydocument.xml","form_type":"4"}},{"id":3727437,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2018-12-18T19:48:53.000Z","date":"2018-12-16","kind":"exercise","acquired":false,"shares":13968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vested and were settled in common stock on December 16, 2018."}],"balance_after":41907,"derivative":{"exercise_price":0,"expiration_date":"2021-12-17","underlying":"Common Stock","underlying_shares":13968},"source":{"system":"sec-edgar","filing":"0001562180-18-005029","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018005029/primarydocument.xml","form_type":"4"}},{"id":3727436,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2018-12-18T19:48:53.000Z","date":"2018-12-16","kind":"exercise","acquired":false,"shares":13083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vested and were settled in common stock on December 16, 2018."}],"balance_after":26166,"derivative":{"exercise_price":0,"expiration_date":"2020-12-16","underlying":"Common Stock","underlying_shares":13083},"source":{"system":"sec-edgar","filing":"0001562180-18-005029","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018005029/primarydocument.xml","form_type":"4"}},{"id":3727435,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-18T19:48:53.000Z","date":"2018-12-14","kind":"grant","acquired":true,"shares":315750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in four equal annual installments beginning on December 16, 2019."}],"balance_after":315750,"derivative":{"exercise_price":15.97,"expiration_date":"2028-12-16","underlying":"Common Stock","underlying_shares":315750},"source":{"system":"sec-edgar","filing":"0001562180-18-005029","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018005029/primarydocument.xml","form_type":"4"}},{"id":3727434,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2018-12-18T19:48:53.000Z","date":"2018-12-14","kind":"grant","acquired":true,"shares":52625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock. The RSUs vest and will be settled in common stock in four equal annual installments beginning on December 16, 2019."}],"balance_after":52625,"derivative":{"exercise_price":0,"expiration_date":"2022-12-20","underlying":"Common Stock","underlying_shares":52625},"source":{"system":"sec-edgar","filing":"0001562180-18-005029","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018005029/primarydocument.xml","form_type":"4"}},{"id":3727433,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2018-12-18T19:48:53.000Z","date":"2018-12-16","kind":"tax_withholding","acquired":false,"shares":11898,"price":15.97,"value":190011.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person."}],"balance_after":174620,"source":{"system":"sec-edgar","filing":"0001562180-18-005029","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018005029/primarydocument.xml","form_type":"4"}},{"id":3727432,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2018-12-18T19:48:53.000Z","date":"2018-12-16","kind":"exercise","acquired":true,"shares":27051,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares issued upon settlement of Restricted Stock Units (\"RSUs\") granted on December 27, 2016 and December 16, 2017, as a result of the vesting of one fourth of such RSUs."}],"balance_after":186518,"source":{"system":"sec-edgar","filing":"0001562180-18-005029","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018005029/primarydocument.xml","form_type":"4"}},{"id":3880632,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2018-06-29T16:22:19.000Z","date":"2018-06-27","kind":"exercise","acquired":false,"shares":32068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"RSUs representing 32,068 shares of common stock vested upon the achievement of a second milestone relating to the return of rights to binimetinib to the Issuer on or prior to the fourth anniversary of the grant date, subject to continued service with the Issuer as of the vesting date."}],"balance_after":0,"derivative":{"exercise_price":0,"expiration_date":"2018-08-18","underlying":"Common Stock","underlying_shares":32068},"source":{"system":"sec-edgar","filing":"0001562180-18-003130","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018003130/primarydocument.xml","form_type":"4"}},{"id":3880631,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2018-06-29T16:22:19.000Z","date":"2018-06-27","kind":"sale","acquired":false,"shares":17964,"price":17.74,"value":318681.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported for these shares is the weighted average sale price of transactions made at prices from $17.60 to $17.84. Details of actual prices for shares sold are available from the Issuer upon request."}],"balance_after":159467,"source":{"system":"sec-edgar","filing":"0001562180-18-003130","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018003130/primarydocument.xml","form_type":"4"}},{"id":3880630,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2018-06-29T16:22:19.000Z","date":"2018-06-27","kind":"tax_withholding","acquired":false,"shares":14104,"price":18.5,"value":260924.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person."}],"balance_after":177431,"source":{"system":"sec-edgar","filing":"0001562180-18-003130","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018003130/primarydocument.xml","form_type":"4"}},{"id":3880629,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2018-06-29T16:22:19.000Z","date":"2018-06-27","kind":"exercise","acquired":true,"shares":32068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares released on vesting of Restricted Stock Units (\"RSUs\") granted to the reporting person on August 18, 2014. The grant of these RSUs was previously reported on Table II."}],"balance_after":191535,"source":{"system":"sec-edgar","filing":"0001562180-18-003130","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018003130/primarydocument.xml","form_type":"4"}},{"id":3973805,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2018-04-03T18:48:38.000Z","date":"2018-04-01","kind":"exercise","acquired":false,"shares":9844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The remaining RSUs vest and will be settled in stock in two equal annual installments on April 1, 2019 and 2020."}],"balance_after":19688,"derivative":{"exercise_price":0,"expiration_date":"2020-04-01","underlying":"Common Stock","underlying_shares":9844},"source":{"system":"sec-edgar","filing":"0001562180-18-001801","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018001801/primarydocument.xml","form_type":"4"}},{"id":3973804,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2018-04-03T18:48:38.000Z","date":"2018-04-01","kind":"tax_withholding","acquired":false,"shares":8675,"price":16.32,"value":141576.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person."}],"balance_after":159467,"source":{"system":"sec-edgar","filing":"0001562180-18-001801","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018001801/primarydocument.xml","form_type":"4"}},{"id":3973803,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2018-04-03T18:48:38.000Z","date":"2018-04-01","kind":"exercise","acquired":true,"shares":9844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares issued upon settlement of Restricted Stock Units (\"RSUs\") granted by the Issuer on April 1, 2016 as a result of the vesting of one fourth of such RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 9,844 unvested Restricted Stock Units (\"RSUs\") awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs, and (ii) 9,844 shares of common stock issued upon the vesting of these RSU's on April 1, 2018."}],"balance_after":168142,"source":{"system":"sec-edgar","filing":"0001562180-18-001801","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018001801/primarydocument.xml","form_type":"4"}},{"id":4126845,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-18","kind":"exercise","acquired":false,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The option vested in four equal annual installments beginning on April 1, 2015."}],"balance_after":87500,"derivative":{"exercise_price":4.63,"expiration_date":"2024-04-01","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126844,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-18","kind":"exercise","acquired":false,"shares":89634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The option vested in four equal annual installments beginning on July 23, 2014."}],"balance_after":0,"derivative":{"exercise_price":4.91,"expiration_date":"2023-03-28","underlying":"Common Stock","underlying_shares":89634},"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126843,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-18","kind":"exercise","acquired":false,"shares":20366,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":4.91,"exercise_date":"2017-07-23","expiration_date":"2023-03-28","underlying":"Common Stock","underlying_shares":20366},"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126842,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-18","kind":"exercise","acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The option vested in four equal annual installments beginning on July 23, 2013."}],"balance_after":0,"derivative":{"exercise_price":5.14,"expiration_date":"2022-07-31","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126841,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-16","kind":"grant","acquired":true,"shares":335250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option vests in four equal annual installments beginning on December 16, 2018."}],"balance_after":335250,"derivative":{"exercise_price":10.92,"expiration_date":"2027-12-16","underlying":"Common Stock","underlying_shares":335250},"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126840,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-16","kind":"grant","acquired":true,"shares":55875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2018."}],"balance_after":55875,"derivative":{"exercise_price":0,"expiration_date":"2021-12-17","underlying":"Common Stock","underlying_shares":55875},"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126839,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-16","kind":"exercise","acquired":false,"shares":13082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vested on December 16, 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Consists of remaining unvested RSUs awarded to the reporting person for no additional cash consideration on December 16, 2016, which vest in three equal remaining installments beginning December 16, 2018, and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person."}],"balance_after":39249,"derivative":{"exercise_price":0,"expiration_date":"2020-12-16","underlying":"Common Stock","underlying_shares":13082},"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126838,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-18","kind":"sale","acquired":false,"shares":282874,"price":10.72,"value":3032409.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request."}],"balance_after":158298,"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126837,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-18","kind":"exercise","acquired":true,"shares":87500,"price":4.63,"value":405125.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 19,687 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs."}],"balance_after":441172,"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126836,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-18","kind":"exercise","acquired":true,"shares":89634,"price":4.91,"value":440102.94,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 19,687 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs."}],"balance_after":353672,"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126835,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-18","kind":"exercise","acquired":true,"shares":20366,"price":4.91,"value":99997.06,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 19,687 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs."}],"balance_after":264038,"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126834,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-18","kind":"exercise","acquired":true,"shares":200000,"price":5.14,"value":1028000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 19,687 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs."}],"balance_after":243672,"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126833,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-16","kind":"tax_withholding","acquired":false,"shares":6094,"price":10.92,"value":66546.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person."}],"balance_after":43672,"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4126832,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2017-12-19T21:05:29.000Z","date":"2017-12-16","kind":"exercise","acquired":true,"shares":13082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares issued upon settlement of Restricted Stock Units (\"RSUs\") granted by the Issuer on December 27, 2016 as a result of the vesting of one fourth of such RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 19,687 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs."}],"balance_after":49766,"source":{"system":"sec-edgar","filing":"0001562180-17-003957","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003957/primarydocument.xml","form_type":"4"}},{"id":4356965,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2017-04-06T20:31:05.000Z","date":"2017-04-01","kind":"tax_withholding","acquired":false,"shares":9167,"price":8.94,"value":81952.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment to form 4 is being filed to correct number of shares withheld to satisfy the reporting person's tax withholding obligations in connection with the vesting of Restricted Stock Units previously reported on a form 4 by the reporting person. No other information in such form 4 is being amended."}],"balance_after":36684,"source":{"system":"sec-edgar","filing":"0001562180-17-001485","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001485/primarydocument.xml","form_type":"4/A","original_submission_date":"2017-04-04"}},{"id":4362039,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2017-04-04T21:42:18.000Z","date":"2017-04-01","kind":"exercise","acquired":false,"shares":9843,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued on settlement of Restricted Stock Units (\"RSUs\") granted to the reporting person, of which 3,148 shares were withheld upon vesting to satisfy tax. The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Consists of unvested RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person."}],"balance_after":29532,"derivative":{"exercise_price":0,"expiration_date":"2020-04-01","underlying":"Common Stock","underlying_shares":9843},"source":{"system":"sec-edgar","filing":"0001562180-17-001464","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001464/primarydocument.xml","form_type":"4"}},{"id":4362038,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2017-04-04T21:42:18.000Z","date":"2017-04-01","kind":"tax_withholding","acquired":false,"shares":6293,"price":8.94,"value":56259.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld to satisfy tax withholding obligations of the reporting person in connection with the vesting of RSUs held by the reporting person."}],"balance_after":39558,"source":{"system":"sec-edgar","filing":"0001562180-17-001464","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001464/primarydocument.xml","form_type":"4"}},{"id":4362037,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2017-04-04T21:42:18.000Z","date":"2017-04-01","kind":"exercise","acquired":true,"shares":9843,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued on settlement of Restricted Stock Units (\"RSUs\") granted to the reporting person, of which 3,148 shares were withheld upon vesting to satisfy tax. The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 19,688 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs."}],"balance_after":45851,"source":{"system":"sec-edgar","filing":"0001562180-17-001464","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001464/primarydocument.xml","form_type":"4"}},{"id":4510695,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-29T17:52:54.000Z","date":"2016-12-27","kind":"grant","acquired":true,"shares":313989,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning on December 16, 2017."}],"balance_after":313989,"derivative":{"exercise_price":8.79,"expiration_date":"2026-12-27","underlying":"Common Stock","underlying_shares":313989},"source":{"system":"sec-edgar","filing":"0001562180-16-003918","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218016003918/primarydocument.xml","form_type":"4"}},{"id":4510694,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":45118,"kind":"person","name":"Robbins Andrew R","position":1,"cik":"0001590157","reported_name":"Robbins Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2016-12-29T17:52:54.000Z","date":"2016-12-27","kind":"grant","acquired":true,"shares":52331,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2017."}],"balance_after":52331,"derivative":{"exercise_price":0,"expiration_date":"2020-12-28","underlying":"Common Stock","underlying_shares":52331},"source":{"system":"sec-edgar","filing":"0001562180-16-003918","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218016003918/primarydocument.xml","form_type":"4"}}]}